HR POSITIVE/HER-2 NEGATIVE BREAST CANCER
Clinical trials for HR POSITIVE/HER-2 NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR POSITIVE/HER-2 NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HR POSITIVE/HER-2 NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug boosts chemo to fight breast cancer before surgery
Disease control Not yet recruitingThis study is testing whether adding an immunotherapy drug called eftilagimod alpha (Efti) to standard chemotherapy given before surgery can help eliminate more cancer in patients with early-stage, hormone-positive, HER2-negative breast cancer. The main goal is to see if this com…
Matched conditions: HR POSITIVE/HER-2 NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: George Washington University • Aim: Disease control
Last updated Apr 01, 2026 14:40 UTC
-
New targeted drug trial launches for Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage study is testing a new targeted drug called CGT6297 in adults with advanced solid tumors that have a specific genetic change called a PIK3CA mutation. The main goals are to find a safe dose and see if the drug shows early signs of helping to shrink tumors. The st…
Matched conditions: HR POSITIVE/HER-2 NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC